Return to content in this issue


Omalizumab as Third-Line Therapy for Urticaria During Pregnancy

Ensina LF1,2, Cusato-Ensina AP2, Camelo-Nunes IC1, Solé D1

1Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil
2CPAlpha Clinical Research, Barueri, Brazil

J Investig Allergol Clin Immunol 2017; Vol 27(5) : 326-327
doi: 10.18176/jiaci.0179

Key words: Urticaria, Omalizumab, Angioedema, Therapeutics